Evidence map›Paper›PMID 21347238›Full record

ArticlePloS one2011

Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease.

Shankar Mukherjee, Fabiana S Machado, Huang Huang, Helieh S Oz, Linda A Jelicks, Cibele M Prado, Wade Koba, Eugene J Fine, Dazhi Zhao, Stephen M Factor and 4 more

Abstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Towards a map of the immune system manipulation network byFrontiers in cellular and infection microbiology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Old Yellow Enzyme fromFrontiers in immunology · 2018
    Article
  13. Article
  14. Article
  15. Response toFrontiers in microbiology · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shankar MukherjeeDivision of Parasitology, Department of Pathology, Albert Einstein College of Medicine, New York City, New York, United States of America.
Fabiana S Machado
Huang Huang
Helieh S Oz
Linda A Jelicks
Cibele M Prado
Wade Koba
Eugene J Fine
Dazhi Zhao
Stephen M Factor
J Elias Collado
Louis M Weiss
Herbert B Tanowitz
Anthony W Ashton

Funding

T. cruzi: pathogenesis modulation by eicosanoidsR01AI076248 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI TANOWITZ, HERBERT BERNARD · 2008 to 2012
$2.3M
Interhemispheric Research/Training in Infectious DiseaseD43TW007129 · FIC · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI TANOWITZ, HERBERT BERNARD · 2004 to 2013
$1.7M
FIC NIH HHS D43 TW007129FIC NIH HHS D43TW007129NIAID NIH HHS AI-76248NIAID NIH HHS R01 AI076248
6 · The paper itself

Abstract

Chagas disease, caused by infection with Trypanosoma cruzi, is an important cause of cardiovascular disease. It is increasingly clear that parasite-derived prostaglandins potently modulate host response and disease progression. Here, we report that treatment of experimental T. cruzi infection (Brazil strain) beginning 5 days post infection (dpi) with aspirin (ASA) increased mortality (2-fold) and parasitemia (12-fold). However, there were no differences regarding histopathology or cardiac structure or function. Delayed treatment with ASA (20 mg/kg) beginning 60 dpi did not increase parasitemia or mortality but improved ejection fraction. ASA treatment diminished the profile of parasite- and host-derived circulating prostaglandins in infected mice. To distinguish the effects of ASA on the parasite and host bio-synthetic pathways we infected cyclooxygenase-1 (COX-1) null mice with the Brazil-strain of T. cruzi. Infected COX-1 null mice displayed a reduction in circulating levels of thromboxane (TX)A(2) and prostaglandin (PG)F(2α). Parasitemia was increased in COX-1 null mice compared with parasitemia and mortality in ASA-treated infected mice indicating the effects of ASA on mortality potentially had little to do with inhibition of prostaglandin metabolism. Expression of SOCS-2 was enhanced, and TRAF6 and TNFα reduced, in the spleens of infected ASA-treated mice. Ablation of the initial innate response to infection may cause the increased mortality in ASA-treated mice as the host likely succumbs more quickly without the initiation of the "cytokine storm" during acute infection. We conclude that ASA, through both COX inhibition and other "off-target" effects, modulates the progression of acute and chronic Chagas disease. Thus, eicosanoids present during acute infection may act as immunomodulators aiding the transition to and maintenance of the chronic phase of the disease. A deeper understanding of the mechanism of ASA action may provide clues to the differences between host response in the acute and chronic T. cruzi infection.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalAspirinChagas DiseaseChronic DiseaseCyclooxygenase 1CytokinesEicosanoidsGene DeletionMaleMiceParasitemiaStroke VolumeThromboxane-A SynthaseTime FactorsTrypanosoma cruziAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 1CytokinesEicosanoidsThromboxane-A Synthase

Identifiers

PMID21347238
PMCPMC3039660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.